EXPRS2 Stock Overview
Through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ExpreS2ion Biotech Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 20.80 |
| 52 Week High | SEK 164.00 |
| 52 Week Low | SEK 17.84 |
| Beta | 1.73 |
| 1 Month Change | 8.11% |
| 3 Month Change | -50.10% |
| 1 Year Change | -77.29% |
| 3 Year Change | -98.65% |
| 5 Year Change | -87.88% |
| Change since IPO | -90.80% |
Recent News & Updates
Shareholder Returns
| EXPRS2 | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -14.8% | 1.2% | -2.7% |
| 1Y | -77.3% | 13.8% | 4.6% |
Return vs Industry: EXPRS2 underperformed the Swedish Biotechs industry which returned 13.8% over the past year.
Return vs Market: EXPRS2 underperformed the Swedish Market which returned 4.6% over the past year.
Price Volatility
| EXPRS2 volatility | |
|---|---|
| EXPRS2 Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: EXPRS2's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: EXPRS2's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 18 | Bent Frandsen | www.expres2ionbio.com |
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor. It is also developing ES2B-I002, a cytomegalovirus vaccine candidate to treat infectious diseases.
ExpreS2ion Biotech Holding AB (publ) Fundamentals Summary
| EXPRS2 fundamental statistics | |
|---|---|
| Market cap | SEK 43.69m |
| Earnings (TTM) | -SEK 34.00m |
| Revenue (TTM) | SEK 7.93m |
5.5x
P/S Ratio-1.3x
P/E RatioIs EXPRS2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXPRS2 income statement (TTM) | |
|---|---|
| Revenue | SEK 7.93m |
| Cost of Revenue | SEK 4.07m |
| Gross Profit | SEK 3.86m |
| Other Expenses | SEK 37.86m |
| Earnings | -SEK 34.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | -16.19 |
| Gross Margin | 48.66% |
| Net Profit Margin | -428.76% |
| Debt/Equity Ratio | 0.5% |
How did EXPRS2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 11:12 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ExpreS2ion Biotech Holding AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Berzhanin | Pareto Securities |